IMNR – The Immune Response Corporation
StockGuru Profile IMNR
The Immune Response Corporation (OTCBB:IMNR), is an immuno-pharmaceutical company. Stock Guru has scheduled several interviews with IMNR’s scientists and officers.
A large NeuroVax(TM) trial, to start imminently, will provide the opportunity to further explore the FOXP3+ regulatory T-cell mechanism of action that was demonstrated in IMNR’s Phase IIa trial data presented this past April at AAN.
As evidenced by the article entitled “Peacekeepers of the Immune System” in the latest issue of Scientific American, the role of FOXP3+ regulatory T-cells in controlling autoimmune disease has become a very important topic in immunology in the last 18 months.
NeuroVax(TM) is the first therapeutic that has been shown in clinical trials to boost FOXP3+ levels in patients with MS. IMNR’s new trial will generate substantial additional data related to this mechanism which has the potential to aid scientists in a better understanding of the potential for NeuroVax(TM) to alter the course of MS by amplifying FOXP3+ responses.
Beyond MS, IMNR has confidence that the approach that impacts on the FOXP3+ immune regulatory mechanism could well prove to be a major breakthrough for autoimmune disease in general including psoriasis and rheumatoid arthritis (RA) for which IMNR has TCR peptide-based therapeutic vaccines (Zorcell(TM) for psoriasis and RaVax(TM) for RA) with Investigational New Drug Applications with the FDA.
During the next year, IMNR plans to initiate new clinical work with at least one of these products aimed at evaluating the effect on FOXP3+.
This work will expand IMNR’s autoimmune product pipeline and position IMRN to further exploit the potential of their intellectual property position with respect to clinical applications of vaccines and diagnostics that impact FOXP3+. HIV/AIDS — IR103
Recent HIV/AIDS studies indicate that a patient’s CD4+ count is the most significant marker of HIV disease progression. An immune based therapy like IR103 that can impact CD4+ count may well be an enormous contribution to the current treatment landscape.
Between now and the end of the year, IMNR intends to complete enrollment of over 200 antiretroviral drug-naive patients in our expanded Phase II clinical trials of IR103 in Italy, France, the United Kingdom, and Canada. These trials, for which IMNR has already enrolled over 100 patients, are designed to run one year and provide a robust clinical and immunological profile of IR103. IMNR plans to leverage this data to design pivotal trials of this product and to help drive new collaborations to support their global development program.
The interim results from these open label Phase II clinical trials should be available soon, which will provide important data regarding the impact of IR013 on CD4+ counts and other important markers.
REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.
For further information contact:
ROI Group Associates
39 Broadway; NY, NY 10006
212.495.0744
MDodge@roiny.com
Source:
IMNR — Immune Response Corp. (The)
5931 Darwin Court
Carlsbad, CA 92008
Website: http://www.imnr.com
Phone: 760-431-7080
Forward Looking Statement and Safe Harbor: Any information regarding The Immune Response Corporation (”IMNR”) in this communication is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO ITS OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. ROI Group Associates, Inc. (”ROI”) is the investor relations counsel for IMNR and accepts compensation from the IMNR for this effort, including a monthly cash retainer and restricted stock. Under the terms of its investor relations Service Agreement, ROI has agreed not to sell any of the IMNR restricted stock received as compensation under the Service Agreement during the entire term of its engagement as IMNR’s investor relations counsel pursuant to this Service Agreement. ROI shall be under no obligation to update readers about any restrictions on its trading activities regarding IMNR.
In addition to MS, IMNR has opened Investigational New Drug Applications (IND) with the U.S. Food and Drug Administration (FDA) for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis. IR103 is based on their patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE® , our first-generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. IMNR is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naïve HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. In early 2006 IMNR made a strategic decision to accelerate the development of IR103, rather than pursue a Phase III trial with REMUNE® . All of IMNR products are still in the development stage. IMNR has never had revenues from the sale of products. IMNR was founded in 1986.
Forward Looking Statement: This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in IMNR’s periodic filings with the U.S. Securities and Exchange Commission.
Disclosure: Pentony Enterprises LLC was compensated $50,000 from ROI Group Associates Inc. for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco , Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com . Email: Publisher@stockguru.com.